Mylan, Pfizer Say EpiPen Antitrust Suits Don't Need MDL
Mylan NV and Pfizer Inc. on Wednesday each urged the Judicial Panel on Multidistrict Litigation not to consolidate antitrust litigation against the drugmakers, arguing the majority of cases are already working...To view the full article, register now.
Already a subscriber? Click here to view full article